For instance, the RIPK1 inhibitor GSK0547 significantly suppresses tumor growth in vivo, promotes M1 macrophage polarization, and reprograms TAMs to activate CD4+ Th1/Th17 and CD8+ T cells, and demonstrates synergistic efficacy in combination with PD-1 inhibitors or ICOS agonists, resulting in significantly prolonged survival [101]. Here, RIPK1 is linked to neoplasm.